Cardiac neuronal imaging with 123I-meta-iodobenzylguanidine in heart failure: implications of endpoint selection and quantitative analysis on clinical decisions

Petretta, Mario; Pellegrino, Teresa; Cuocolo, Alberto

doi:10.1007/s00259-014-2827-2

Cited by 8 publications

(6 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In particular, high-energy photons in 123 I, particularly the 529-keV photon (1.4%), result in numeric differences in measurements from LE-and ME-collimated images. Therefore, a dichotomous manner of risk assessment (low risk vs. high risk) with an HMR threshold may be questionable (30). However, it is crucial and possible to standardize 123 I-MIBG parameters (HMR and WR) for clinical application in the management of HF.…”

Section: Standardization Of Hmr For Prognostic Evaluationmentioning

confidence: 99%

Cardiac ¹²³I-MIBG Imaging for Clinical Decision Making: 22-Year Experience in Japan

Nakajima

Nakata

2015

J Nucl Med

View full text Add to dashboard Cite

Cardiac neuroimaging with 123 I-metaiodobenzylguanidine ( 123 I-MIBG) has been officially used in clinical practice in Japan since 1992. The nuclear cardiology guidelines of the Japanese Circulation Society, revised in 2010, recommended cardiac 123 I-MIBG imaging for the management of heart failure (HF) patients, particularly for the assessment of HF severity and prognosis of HF patients. Consensus in North American and European countries regarding incorporation into clinical practice, however, has not been established yet. This article summarizes 22 y of clinical applications in Japan of 123 I-MIBG imaging in the field of cardiology; these applications are reflected in cardiology guidelines, including recent methodologic advances. A standardized cardiac 123 I-MIBG parameter, the heartto-mediastinum ratio (HMR), is the basis for clinical decision making and enables common use of parameters beyond differences in institutions and studies. Several clinical studies unanimously demonstrated its potent independent roles in prognosis evaluation and risk stratification irrespective of HF etiologies. An HMR of less than 1.6−1.8 and an accelerated washout rate are recognized as high-risk indicators of pump failure death, sudden cardiac death, and fatal arrhythmias and have independent and incremental prognostic values together with known clinical variables, such as left ventricular ejection fraction and brain natriuretic peptide. Another possible use of this imaging technique is the selection of therapeutic strategy, such as pharmacologic treatment and nonpharmacologic treatment with an implantable cardioverter-defibrillator or cardiac resynchronization device; however, this possibility remains to be investigated. Recent multiple-cohort database analyses definitively demonstrated that patients who were at low risk for lethal events and who were defined by an HMR of greater than 2.0 on 123 I-MIBG studies had a good long-term prognosis. Future investigations of cardiac 123 I-MIBG imaging will contribute to better risk stratification of low-risk and high-risk populations, to the establishment of costeffective use of this imaging technique for the management of HF patients, and to worldwide acceptance of this imaging technique in clinical cardiology practice.

show abstract

Section: Standardization Of Hmr For Prognostic Evaluationmentioning

confidence: 99%

Cardiac ¹²³I-MIBG Imaging for Clinical Decision Making: 22-Year Experience in Japan

Nakajima

Nakata

2015

J Nucl Med

View full text Add to dashboard Cite

show abstract

“…O MIBG-123 I fica retido e localizado nas terminações nervosas simpáticas cardíacas, com imagens cintilográficas obtidas por gama-câmara convencional. [322][323][324][325] O radioisótopo iodo-123 emite, predominantemente, fótons gama com energia de 159 keV e meia-vida física de 13,2 horas, sendo a aquisição das imagens fácil e bem tolerada. O MIBG-123 I é muito usado na Europa, Japão e mais recentemente foi aprovado nos EUA para uso cardíaco.…”

Section: Cintilografia Cardíaca Com Mibg-123 Iunclassified

“…Visualmente e de forma semiquantitativa, dois parâmetros fundamentais são analisados: a relação da captação coração/mediastino (razão coração/mediastino ou RC/M) precoce (imagens de 15 minutos após a injeção) e tardia (imagens de 4 horas após a injeção) e a taxa de clareamento miocárdico do MIBG-123 I (washout rate -WR). [322][323][324][327][328][329][330] Os valores normais da RC/M variam de 1,9 a 2,8 com média aproximada de 2,2 ± 0,3 nas imagens tardias, sendo que resultados ≥ 1,6 são preditivos de menor risco. 31 A RC/M reflete a densidade de receptores e, provavelmente, retrata a integridade das terminações nervosas pré-sinápticas e a função do receptor uptake1.…”

Section: Cintilografia Cardíaca Com Mibg-123 Iunclassified

Atualização da Diretriz Brasileira de Cardiologia Nuclear – 2020

Mastrocola

Amorim

Vítola³

et al. 2020

ABC Cardiol

View full text Add to dashboard Cite

show abstract

“…3 As well, myocardial imaging with 123Imetaiodobenzylguanidine (MIBG) is a recognized imaging modality for non-invasive assessment of global and regional cardiac sympathetic innervation related to heart failure. 4,5 The association of myocardial perfusion and innervation imaging has been used in patients after myocardial infarction as well in patients with hypertrophic and dilated cardiomyopathy. 6,7 In particular, the combined use of these two different imaging modalities provided useful informations in identifying the presence of viable but sympathetically denervated myocardial areas, defined as trigger zone.…”

Section: See Related Article Pp 1361-1369mentioning

confidence: 99%

Dual isotope and multidetector camera: The best choices for a specific end-point

Assante

Acampa

2017

Journal of Nuclear Cardiology

View full text Add to dashboard Cite

Cardiac neuronal imaging with 123I-meta-iodobenzylguanidine in heart failure: implications of endpoint selection and quantitative analysis on clinical decisions

Cited by 8 publications

References 20 publications

Cardiac ¹²³I-MIBG Imaging for Clinical Decision Making: 22-Year Experience in Japan

Cardiac ¹²³I-MIBG Imaging for Clinical Decision Making: 22-Year Experience in Japan

Atualização da Diretriz Brasileira de Cardiologia Nuclear – 2020

Dual isotope and multidetector camera: The best choices for a specific end-point

Contact Info

Product

Resources

About

Cardiac neuronal imaging with 123I-meta-iodobenzylguanidine in heart failure: implications of endpoint selection and quantitative analysis on clinical decisions

Cited by 8 publications

References 20 publications

Cardiac 123I-MIBG Imaging for Clinical Decision Making: 22-Year Experience in Japan

Cardiac 123I-MIBG Imaging for Clinical Decision Making: 22-Year Experience in Japan

Atualização da Diretriz Brasileira de Cardiologia Nuclear – 2020

Dual isotope and multidetector camera: The best choices for a specific end-point

Contact Info

Product

Resources

About

Cardiac ¹²³I-MIBG Imaging for Clinical Decision Making: 22-Year Experience in Japan

Cardiac ¹²³I-MIBG Imaging for Clinical Decision Making: 22-Year Experience in Japan